ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...
BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...
Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...
Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...
Clinical Trials Arena on MSN
BioInvent’s mAb plus Keytruda boosts ORR in mid-stage ovarian cancer trial
The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.
Eterna Therapeutics announced promising preclinical results for its lead cell therapy, ERNA-101, aimed at treating ovarian cancer by activating the immune system. In a study conducted at MD Anderson, ...
In the future, scientists could use drugs made from cannabis to fight ovarian cancer. A team of scientists testing the ...
Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback